AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10451073 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis affected body surface area (BSA)
Number of subjects: 221
Study 10451073 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of psoriasis
Number of subjects: 221
Study 10451073 — intervention group
Group type: COMPARATOR
Intervention: Comparison of BSA by ethnicity
Number of subjects: 221
Study 10451073 — intervention group
Group type: COMPARATOR
Intervention: Target lesion severity by ethnicity
Number of subjects: 221
Study 10451073 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriatic nail disease and DIP joint involvement
Number of subjects: 221
Study 8633914 — intervention group
Group type: EXPERIMENTAL
Intervention: New hub model
Number of subjects: 151
Study 8633914 — intervention group
Group type: COMPARATOR
Intervention: Standard connectors (control group)
Number of subjects: 151
Study 1767056 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol 150 mgI/ml (250 ml)
Number of subjects: 60
Study 1767056 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol 370 mgI/ml (100 ml)
Number of subjects: 60
Study 6120311 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release aminophylline (mean 683 mg; 10.4 mg/kg)
Number of subjects: 12
Study 6120311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6120311 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release aminophylline
Number of subjects: 12
Study 31980342 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential negative symptoms (anhedonia and avolition)
Number of subjects: 146
Study 31980342 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogia
Number of subjects: 146
Study 31980342 — intervention group
Group type: COMPARATOR
Intervention: Control for neurocognition, antipsychotic medication, and depressive symptoms
Number of subjects: 146
Study 29807441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 240
Study 29807441 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 240
Study 28688269 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticulture therapy in specially designed urban green environments
Number of subjects: 30
Study 28688269 — intervention group
Group type: COMPARATOR
Intervention: Occupational art therapy (control group)
Number of subjects: 30
Study 25577543 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg) with budesonide (400 µg)
Number of subjects: 297
Study 25577543 — intervention group
Group type: COMPARATOR
Intervention: Doxofylline (400 mg) with budesonide (400 µg)
Number of subjects: 297
Study 25577543 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (18 µg) with budesonide (400 µg)
Number of subjects: 297
Study 25577543 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 µg) with budesonide (400 µg)
Number of subjects: 297
Study 24088126 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (5 mg)
Number of subjects: 25
Study 24088126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 21270383 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 560
Study 21270383 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 560
Study 21270383 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron plus zinc supplementation
Number of subjects: 560
Study 21270383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study 18221822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mushroom lunches (339 kcal)
Number of subjects: 0
Study 18221822 — intervention group
Group type: COMPARATOR
Intervention: Meat lunches (783 kcal)
Number of subjects: 0
Study 17215602 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed Information for Parental Coping before Intravenous Procedure (PIPC‐IP)
Number of subjects: 56
Study 17215602 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 14653130 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianlong Xifeng granule (TXG)
Number of subjects: 182
Study 14653130 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo Biloba capsule
Number of subjects: 182
Study 11015996 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5'-DFUR (610 mg/m2/day x 10 days or over) preoperatively
Number of subjects: 171
Study 11015996 — intervention group
Group type: COMPARATOR
Intervention: No treatment preoperatively (Group II)
Number of subjects: 171
Study 11015996 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5'-DFUR (good compliance)
Number of subjects: 171
Study 11015996 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5'-DFUR (poor compliance)
Number of subjects: 171
Study 11015996 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients classified as having curability B (Group I)
Number of subjects: 171
Study 11015996 — intervention group
Group type: COMPARATOR
Intervention: Patients classified as having curability B (Group II)
Number of subjects: 171
Study 9165564 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil 1500 mg orally
Number of subjects: 12
Study 9165564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir 5 mg/kg intravenously
Number of subjects: 12
Study 9165564 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir plus Mycophenolate mofetil
Number of subjects: 12
Study 9165564 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil plus Ganciclovir
Number of subjects: 12
Study 1350482 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg daily
Number of subjects: 20
Study 1350482 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg daily
Number of subjects: 20
Study 1350482 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 6.25 mg daily
Number of subjects: 20
Study 1350482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 4001280 — intervention group
Group type: EXPERIMENTAL
Intervention: Desimipramine (DMI) 25 mg
Number of subjects: 6
Study 4001280 — intervention group
Group type: EXPERIMENTAL
Intervention: Desimipramine (DMI) 15 mg
Number of subjects: 6
Study 4001280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29197219 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg/day of somatropin
Number of subjects: 48
Study 26935819 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarolaner (Simparica™) at a minimum dose of 2 mg/kg
Number of subjects: 160
Study 26935819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 25355697 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly or bimonthly standard 3-day treatment regimens of dihydroartemisinin-piperaquine
Number of subjects: 1000
Study 25355697 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly dosing regimen based on the final model
Number of subjects: 1000
Study 25355697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 23523459 — intervention group
Group type: EXPERIMENTAL
Intervention: Combo stent
Number of subjects: 183
Study 23523459 — intervention group
Group type: COMPARATOR
Intervention: PES
Number of subjects: 183
Study 20888520 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone transdermal patch (T group, n = 24)
Number of subjects: 36
Study 20888520 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P group, n = 12)
Number of subjects: 36
Study 18620759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold knife tonsillectomy
Number of subjects: 90
Study 18620759 — intervention group
Group type: COMPARATOR
Intervention: Thermal welding tonsillectomy
Number of subjects: 90
Study 18620759 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency excision
Number of subjects: 90
Study 16630899 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic hematoma evacuation (SHE)
Number of subjects: 242
Study 16630899 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 242
Study 12744768 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (intravenous followed by optional oral)
Number of subjects: 230
Study 12744768 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (intravenous only)
Number of subjects: 230
Study 12201213 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid treatment (Group 1)
Number of subjects: 20
Study 12201213 — intervention group
Group type: COMPARATOR
Intervention: Observation (Group 2)
Number of subjects: 20
Study 10499052 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle turbinate medialization
Number of subjects: 50
Study 7580707 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra information offered individually
Number of subjects: 1691
Study 7580707 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra information offered in class
Number of subjects: 1691
Study 7580707 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual information)
Number of subjects: 1691
Study 2022677 — intervention group
Group type: EXPERIMENTAL
Intervention: Dangling protocol initiated on postoperative day 6
Number of subjects: 22
Study 2022677 — intervention group
Group type: EXPERIMENTAL
Intervention: Dangling protocol initiated on postoperative day 8
Number of subjects: 22
Study 2022677 — intervention group
Group type: EXPERIMENTAL
Intervention: Dangling protocol initiated on postoperative day 10
Number of subjects: 22
Study 2022677 — intervention group
Group type: COMPARATOR
Intervention: Dangling on postoperative day 6
Number of subjects: 22
Study 7056011 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metaproterenol for four weeks
Number of subjects: 20
Study 7056011 — intervention group
Group type: COMPARATOR
Intervention: Oral theophylline for four weeks
Number of subjects: 20
Study 31495220 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with everolimus-eluting stents
Number of subjects: 1840
Study 31495220 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1840
Study 28079022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifitegrast ophthalmic solution 5.0%
Number of subjects: 711
Study 28079022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 711
Study 26924470 — intervention group
Group type: EXPERIMENTAL
Intervention: eOIT (egg oral immunotherapy)
Number of subjects: 40
Study 26924470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25086123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) treatment
Number of subjects: 102
Study 25086123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 22085872 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril-FA tablet (10 mg enalapril combined with 0.8 mg of FA, high FA group)
Number of subjects: 480
Study 22085872 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril-FA tablet (10 mg enalapril combined with 0.4 mg of FA, low FA group)
Number of subjects: 480
Study 22085872 — intervention group
Group type: COMPARATOR
Intervention: Enalapril only (10 mg, control group)
Number of subjects: 480
Study 19640950 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg anthocyanins twice daily for 12 weeks
Number of subjects: 120
Study 19640950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 17241190 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Consultation Interview (ECI)
Number of subjects: 40
Study 17241190 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 15619106 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.74% THC (low dose)
Number of subjects: 40
Study 15619106 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.93% THC (high dose)
Number of subjects: 40
Study 15619106 — intervention group
Group type: COMPARATOR
Intervention: 0% THC (placebo)
Number of subjects: 40
Study 12138263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 43
Study 12138263 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study 9482769 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin-containing supplement (1.0 g quercetin/d)
Number of subjects: 0
Study 9482769 — intervention group
Group type: COMPARATOR
Intervention: Rice flour placebo
Number of subjects: 0
Study 8023779 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin, 20 mg/day for 6 weeks
Number of subjects: 74
Study 8023779 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin + niacin (titrated to a maximum of 3 g/day for a further 9 weeks)
Number of subjects: 74
Study 8023779 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin + niacin
Number of subjects: 74
Study 8023779 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin (alone)
Number of subjects: 74
Study 2584285 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 2584285 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0
Study 1097198 — intervention group
Group type: EXPERIMENTAL
Intervention: halcinonide 0.1%
Number of subjects: 100
Study 1097198 — intervention group
Group type: COMPARATOR
Intervention: clobetasol propionate cream 0.05%
Number of subjects: 100
Study 29519744 — intervention group
Group type: EXPERIMENTAL
Intervention: Light mask (Noctura 400 Sleep Mask)
Number of subjects: 308
Study 29519744 — intervention group
Group type: COMPARATOR
Intervention: Sham mask (non-light)
Number of subjects: 308
Study 26970427 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of acute bronchiolitis measured by length of stay and need for ventilatory support
Number of subjects: 209
Study 26970427 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 209
Study 26970427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory support
Number of subjects: 209
Study 25690336 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-coil lead system
Number of subjects: 469
Study 25690336 — intervention group
Group type: COMPARATOR
Intervention: Dual-coil lead system
Number of subjects: 469
Study 25690336 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal shock
Number of subjects: 469
Study 25690336 — intervention group
Group type: COMPARATOR
Intervention: Cathodal shock
Number of subjects: 469
Study 24341333 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) group
Number of subjects: 40
Study 24341333 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 40
Study 20536470 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically administered Tbeta4 (0.03%)
Number of subjects: 73
Study 20536470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 17993603 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐adrenergic blockade‐intravenous propranolol (0.2 mg/kg)
Number of subjects: 33
Study 17993603 — intervention group
Group type: EXPERIMENTAL
Intervention: parasympathetic blockade‐intravenous atropine (0.04 mg/kg)
Number of subjects: 33
Study 17993603 — intervention group
Group type: EXPERIMENTAL
Intervention: double blockade with propranolol and atropine
Number of subjects: 33
Study 17993603 — intervention group
Group type: COMPARATOR
Intervention: baseline
Number of subjects: 33
Study 16368440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) chemotherapy (paclitaxel 135 mg/m² IV over 24 h, cisplatin 100 mg/m² IP day 2, paclitaxel 60 mg/m² IP day 8) every 21 days for six cycles
Number of subjects: 205
Study 16368440 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) chemotherapy (alternate regimen for patients unable to receive IP therapy)
Number of subjects: 205
Study 12744096 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber band ligation + local anaesthetic injection (n = 70)
Number of subjects: 142
Study 12744096 — intervention group
Group type: COMPARATOR
Intervention: Rubber band ligation only (n = 72)
Number of subjects: 142
Study 11199189 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest individual lumbar vertebra T-score
Number of subjects: 150
Study 11199189 — intervention group
Group type: COMPARATOR
Intervention: Lumbar spine T-score
Number of subjects: 150
Study 11199189 — intervention group
Group type: COMPARATOR
Intervention: Mid-forearm T-score
Number of subjects: 150
Study 11199189 — intervention group
Group type: COMPARATOR
Intervention: Distal forearm T-score
Number of subjects: 150
Study 11199189 — intervention group
Group type: COMPARATOR
Intervention: Hip T-score
Number of subjects: 150
Study 11199189 — intervention group
Group type: COMPARATOR
Intervention: Correlation between skeletal sites
Number of subjects: 150
Study 11199189 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual lumbar vertebra T-scores
Number of subjects: 150
Study 11199189 — intervention group
Group type: COMPARATOR
Intervention: L2 T-score
Number of subjects: 150
Study 11199189 — intervention group
Group type: COMPARATOR
Intervention: L4 T-score
Number of subjects: 150
Study 11199189 — intervention group
Group type: COMPARATOR
Intervention: Mean difference between L2 and L4 T-scores
Number of subjects: 150
Study 9277382 — intervention group
Group type: COMPARATOR
Intervention: 14% plasma volume expansion (LOW)
Number of subjects: 8
Study 9277382 — intervention group
Group type: EXPERIMENTAL
Intervention: 21% plasma volume expansion (HIGH)
Number of subjects: 8
Study 9277382 — intervention group
Group type: COMPARATOR
Intervention: 0% plasma volume expansion (CON)
Number of subjects: 8
Study 9277382 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise duration
Number of subjects: 8
Study 8421077 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg continuous sc GHRH 1-44 infusion daily for 14 days
Number of subjects: 0
Study 8421077 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg continuous sc GHRH 1-44 infusion daily for 14 days
Number of subjects: 0
Study 8421077 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements before treatment)
Number of subjects: 0
Study 2935497 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg b.i.d.
Number of subjects: 24
Study 2684916 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise test on day 3
Number of subjects: 126
Study 2684916 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion therapy (thrombolysis or coronary angioplasty or both)
Number of subjects: 126
Study 31078312 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 1106
Study 31078312 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 1106
Study 31078312 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex segmentectomy
Number of subjects: 1106
Study 31078312 — intervention group
Group type: EXPERIMENTAL
Intervention: > 20 pack-years of smoking
Number of subjects: 1106
Study 27852617 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain n-3 PUFA (3 g fish oil/d)
Number of subjects: 50
Study 27852617 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 g safflower oil/d)
Number of subjects: 50
Study 26352860 — intervention group
Group type: EXPERIMENTAL
Intervention: DuoResp Spiromax
Number of subjects: 0
Study 26352860 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler
Number of subjects: 0
Study 24340537 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth rinse 0.1%
Number of subjects: 80
Study 24340537 — intervention group
Group type: COMPARATOR
Intervention: Sterile water rinse
Number of subjects: 80
Study 21467302 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous iv infusion of combined GHRH/GHRP‐2 during pharmacological estradiol (E(2); women) or testosterone (T; men) supplementation
Number of subjects: 25
Study 21467302 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous iv infusion of combined GHRH/GHRP‐2
Number of subjects: 25
Study 21467302 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 25
Study 21467302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological estradiol (E(2); women) or testosterone (T; men) supplementation
Number of subjects: 25
Study 20134217 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cross K-wires (group 1; 7 patients, 8 feet)
Number of subjects: 13
Study 20134217 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressive screw (group 2; 6 patients, 8 feet)
Number of subjects: 13
Study 20134217 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 13
Study 16672699 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stent implantation (self-expanding nitinol stent)
Number of subjects: 104
Study 16672699 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty
Number of subjects: 104
Study 14967081 — intervention group
Group type: EXPERIMENTAL
Intervention: Written handout added to verbal explanation
Number of subjects: 50
Study 14967081 — intervention group
Group type: COMPARATOR
Intervention: Verbal explanation only (Control)
Number of subjects: 50
Study 14967081 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study group
Number of subjects: 50
Study 14967081 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific risk - Facial nerve paralysis
Number of subjects: 50
Study 14967081 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific risk - Complete hearing loss
Number of subjects: 50
Study 14967081 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific risk - Dizziness
Number of subjects: 50
Study 14967081 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific risk - Change in taste
Number of subjects: 50
Study 10512076 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 12
Study 10512076 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 12
Study 10512076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10512076 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFE condition
Number of subjects: 12
Study 7557823 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg) every 8 hours for three days
Number of subjects: 8
Study 7557823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1959004 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxerutins (Paroven 500 mg twice daily)
Number of subjects: 138
Study 1959004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138